Congratulations! You have access to the full report.
Download it now.
Download report
Already a Vizient Pharmacy Program member?
Access exclusive member insights
Not already enjoying membership benefits?
Learn how to access exclusive member insights
3.09%
Projected drug price inflation rate
for July 1, 2022-June 30, 2023
Specialty drugs by therapeutic category
What our experts say
Purchases by therapeutic class
While oncology continues to be the highest therapeutic class by drug spend among Vizient members, DMARDs have the highest price change, given the pricing escalations anticipated for adalimumab and etanercept until effective biosimilar competition.
What our experts say
Proof that biosimilars make a difference
Utilization of biosimilar infliximab is decreasing the overall spend for this category of drugs despite the increase in overall utilization. Notice the market share percentage among Vizient members across the previous four quarters.
Percent Vizient Member Infliximab Biosimilar Market Share
Increase in outpatient service line utilization
Adalimumab crosses all three service lines with nine approved indications; but decrease in spend is expected as adalimumab biosimilars are brought to market in 2023.
- 17% Dermatology
- 15% Rheumatology
- 11% Gastroenterology
Source: Vizient data
Diabetes management
Biosimilars now take the top position for diabetes drug spend, with the 2021 approval of interchangeable biosimilar, insulin glargine.
2.69% drug price inflation rate
Source: Vizient data
Let's end drug shortages together
Join the End Drug Shortages Alliance and be a part of the supply chain community driving transparency, quality, and access to additional production of essential medications.
Budget better with pharmacy analytics
Make strategic budgeting decisions, control spend, and ensure contract optimization with Vizient pharmacy analytics solutions.
Connect with our pharmacy experts. We are here to support you.